Current perspectives in drug discovery against tuberculosis from natural products
View/ Open
Date
2015Author
Nguta, Joseph Mwanzia
Appiah-Oponga, Regina
Yeboah-Manu, Dorothy
Addo, Phyllis G.A
Nyarko, Alexander K
Language
enMetadata
Show full item recordAbstract
Currently, one third of the world’s population is latently infected with Mycobacterium tuberculosis (MTB), while 8.9–9.9 million new and relapse cases of tuberculosis (TB) are reported yearly. The renewed research interests in natural products in the hope of discovering new and novel antitubercular leads have been driven partly by the increased incidence of multidrug-resistant strains of MTB and the adverse effects associated with the first- and second-line antitubercular drugs. Natural products have been, and will continue to be a rich source of new drugs against many diseases. The depth and breadth of therapeutic agents that have their origins in the secondary metabolites produced by living organisms cannot be compared with any other source of therapeutic agents. Discovery of new chemical molecules against active and latent TB from natural products requires an interdisciplinary approach, which is a major challenge facing scientists in this field. In order to overcome this challenge, cutting edge techniques in mycobacteriology and innovative natural product chemistry tools need to be developed and used in tandem. The present review provides a cross-linkage to the most recent literature in both fields and their potential to impact the early phase of drug discovery against TB if seamlessly combined.
URI
http://www.sciencedirect.com/science/article/pii/S2212553115000813http://hdl.handle.net/11295/85617
Citation
International Journal of Mycobacteriology Available online 3 June 2015Publisher
Elsevier
Subject
Drug discoveryNatural products
Mycobacterium tuberculosis
Dormancy
Bioassay-guided fractionation
Natural products chemistry